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Abstract
Objective
To characterize clinically and molecularly an early-onset, variably progressive neurodegener-
ative disorder characterized by a cerebellar syndrome with severe ataxia, gaze palsy, dyskinesia,
dystonia, and cognitive decline aﬀecting 11 individuals from 3 consanguineous families.
Methods
We used whole-exome sequencing (WES) (families 1 and 2) and a combined approach based
on homozygosity mapping and WES (family 3). We performed in vitro studies to explore the
eﬀect of the nontruncating SQSTM1 mutation on protein function and the eﬀect of impaired
SQSTM1 function on autophagy. We analyzed the consequences of sqstm1 down-modulation
on the structural integrity of the cerebellum in vivo using zebraﬁsh as a model.
Results
We identiﬁed 3 homozygous inactivating variants, including a splice site substitution
(c.301+2T>A) causing aberrant transcript processing and accelerated degradation of a resulting
protein lacking exon 2, as well as 2 truncating changes (c.875_876insT and c.934_936delin-
sTGA). We show that loss of SQSTM1 causes impaired production of ubiquitin-positive
protein aggregates in response to misfolded protein stress and decelerated autophagic ﬂux. The
consequences of sqstm1 down-modulation on the structural integrity of the cerebellum in
zebraﬁsh documented a variable but reproducible phenotype characterized by cerebellum
anomalies ranging from depletion of axonal connections to complete atrophy. We provide
a detailed clinical characterization of the disorder; the natural history is reported for 2 siblings
who have been followed up for >20 years.
Conclusions
This study oﬀers an accurate clinical characterization of this recently recognized neurode-
generative disorder caused by biallelic inactivating mutations in SQSTM1 and links this phe-
notype to defective selective autophagy.
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Intracellular clearance of damaged cellular constituents is re-
quired for proper cellular function. Autophagy is a major
process involved in this control mechanism,1 and its impaired
or defective function causes toxic stress, which in turn can
drive adverse events, which ultimately may cause cell death.2
Postmitotic neuronal cells are particularly reliant on appro-
priate autophagic function, and dysfunctional autophagy
has been documented to contribute to neurodegenerative
disorders.3–5
SQSTM1 (also known as p62) is a multidomain protein in-
volved in a variety of cellular processes, including intracellular
signaling, oxidative stress response, and apoptosis.6 In addi-
tion, SQSTM1 binds to ubiquitin chains, promoting packag-
ing of ubiquinated cargo by self-oligomerization, and
microtubule-associated protein 1A/1B-light chain 3 (LC3),
serving as a selective autophagy receptor for degradation of
ubiquitinated substrates, and participates in multiple auto-
phagic processes.7 Heterozygous SQSTM1 mutations have
been reported in Paget disease of bone (PDB),8,9 amyo-
trophic lateral sclerosis, and frontotemporal dementia.5,10
More recently, while the present work was underway, biallelic
inactivating SQSTM1 mutations were identiﬁed to underlie
a pediatric neurodegenerative disorder having ataxia, dystonia,
and gaze palsy as major features.11
We report 11 aﬀected individuals from 3 consanguineous
families carrying homozygous inactivating SQSTM1 muta-
tions. We provide a detailed clinical characterization of this
recently recognized neurodegenerative disorder and show
that loss of SQSTM1 function causes a slowdown of auto-
phagic ﬂux and impaired production of ubiquitin-positive
protein aggregates in response to misfolded protein stress.
Finally, we show that suppression of sqstm1 in zebraﬁsh
embryos results in a reproducible phenotype aﬀecting the
structural integrity of the cerebellum.
Methods
Standard protocol approvals, registrations,
and patient consents
Eleven aﬀected individuals from 3 unrelated consanguineous
families were included in the study. Approval from the in-
stitutional ethical committees of the participating centers was
obtained for the genetic studies (Ospedale Pediatrico Bam-
bino Gesu`, EC reference 789; Shahid Sadoughi University
of Medical Sciences, Institutional Review Board reference
700/D/1109), and written informed consent for the genetic
analyses was secured from the guardians of all patients. Af-
fected individuals were examined by experienced neurologists
at their primary care centers, and clinical and imaging data
were jointly reviewed. Families 2 and 3 were identiﬁed
through a clinical genetic survey performed on a large cohort
of Iranian patients with various pediatric neurologic disorders
(≈1,000 families).
Molecular analyses
The genomic analyses were carried out by whole-exome se-
quencing (WES) in families 1 and 2 and by using a combined
approach based on homozygosity mapping analysis in 6
aﬀected individuals coupled to WES performed in a single
aﬀectedmember in family 3. Detailed information on genome-
wide single nucleotide polymorphism (SNP) genotyping,
WES sequencing, and SNP array/WES data analyses is pro-
vided in the data available from Dryad (methods, doi.org/10.
5061/dryad.r1vp879). Variant validation and segregation
analyses were performed by Sanger sequencing.
Biochemical analyses
We obtained primary ﬁbroblasts from the 2 aﬀected individ-
uals (V.5 and V.6, family 1) by dermal skin biopsy and
maintained cultures in high-glucose Dulbecco modiﬁed Eagle
medium with 10% fetal bovine serum and supplements
(Euroclone, Pero, Italy). Inhibition of proteasome- and
autophagy-mediated SQSTM1 degradation was attained by
treating cells with 100 μmol/L MG132 and 200 nmol/L
baﬁlomycin A1 (Sigma-Aldrich, St. Louis, MO), respectively,
for 6 hours. In all experiments evaluating autophagy, we
starved cells in Earle balanced salt solution (EBSS; Gibco,
Thermo Fisher Scientiﬁc, Waltham, MA), as speciﬁed. For
Western blot analyses, cell extracts were separated by 7.5% or
15% sodium dodecyl sulfate–polyacrylamide gel electropho-
resis and transferred to nitrocellulose or polyvinylidene
diﬂuoride membranes (Bio-Rad, Hercules, CA). Blots were
incubated with mouse monoclonal anti-SQSTM1 (1:200;
Santa Cruz Biotechnology, Dallas, TX), rabbit monoclonal
anti-LC3 (1:1000; Cell Signaling, Beverly, MA), mouse
monoclonal anti-β actin (1:500; Sigma-Aldrich), and anti-
rabbit or anti-mouse horseradish peroxidase–coupled second-
ary antibody (1:3000; Thermo Fisher). Immune complexes
were identiﬁed with enhanced chemiluminescence (Promega,
Madison, WI).
To investigate the eﬀect of loss of SQSTM1 function in the
formation of inclusion bodies containing ubiquitinated pro-
teins, we treated primary cells with 5 μg/mL puromycin (2
hours) and analyzed cells by confocal microscopy.We assessed
Glossary
BSA = bovine serum albumin; CCCP = protonophore carbonyl cyanide m-chlorophenyl hydrazone; DQ = dye-conjugated;
EBSS = Earle balanced salt solution; Ig = immunoglobulin; LC3 = microtubule-associated protein 1A/1B-light chain 3;MO =
morpholino oligonucleotide; OXPHOS = oxidative phosphorylation; PDB = Paget disease of bone; SNP = single nucleotide
polymorphism; WES = whole-exome sequencing.
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autolysosome function by using a red BODIPY dye-conjugated
(DQ) bovine serum albumin (BSA; Invitrogen, Carlsbad,
CA)–based assay.12 Control and patient ﬁbroblasts were in-
cubated with the BSA derivative (10 μg/mL) (1 hour, 37°C) in
complete culture medium and then in starvation medium
(EBSS) (5 and 16 hours). We assessed proteolysis of this BSA
derivative by release of ﬂuorescence (590 nm) using confocal
microscopy.
We measured mitochondrial ATP content and complex V
activity in primary ﬁbroblasts (V.5, family 1) and an age-
matched control, as reported.13 To display the mitochondrial
network arrangement, cells were ﬁxed and permeabilized with
methanol:acetone (2:1) for 10 minutes at room temperature;
then a blocking solution (5% BSA in phosphate-buﬀered sa-
line) was used. The polyclonal rabbit TOMM20 antibody
(Santa Cruz Biotechnology) was applied overnight and vi-
sualized with Alexa Fluor 647 secondary antibody (Jackson
ImmunoResearch, West Grove, PA), both at 1:500 dilution.
Images were acquired with a ﬂuorescence inverted micro-
scope (Leica DMi8, Leica Biosystems, Newcastle, UK). An
average of 8 image planes were obtained along the z-axis
(0.2-μm increments) with LASX 3.0.4 (Leica). We induced
mitochondrial depolarization using 20 μmol/L protonophore
carbonyl cyanide m-chlorophenyl hydrazine (CCCP) for
3 hours.
Confocal laser scanning microscopy experiments used 20 ×
103 cells seeded in 24-well cluster plates on 12-mm cover-
glasses and cultured in complete medium (48 hours), as de-
scribed.14 Cells were stained with mouse monoclonal
immunoglobulin (Ig) G anti-SQSTM1 (1:5; Santa Cruz),
rabbit polyclonal IgG anti-LC3B (1:100; Novus Biologicals,
Littleton, CO), mouse polyclonal IgM anti-polyubiquitin (1:
20; FK1, Enzo Life Sciences), and goat anti-mouse IgG, goat
anti-mouse IgM, or goat anti-rabbit Alexa Fluor 488–, 594–,
or 647–conjugated AﬃniPure F(ab9)2 secondary antibodies
(1:200; Molecular Probes, Eugene, OR). After staining, cov-
erslips were rinsed and mounted on slides with Vectashield
mounting medium (Vector Laboratories, Burlingame, CA)
containing 1.5 μg/mL DAPI. Observations were performed
on a Leica TCS SP2 AOBS apparatus. Image acquisition and
processing were performed as reported.14 Signals from dif-
ferent ﬂuorescent probes were taken in sequential scanning
mode, and >50 ﬁelds (10 cells per ﬁeld on average) were
analyzed for each labeling condition. Representative results
are shown.
Zebrafish studies
Two splicing-blocking antisense morpholino oligonucleotides
(MOs) targeting sqstm1 exon 2 and exon 4 were obtained from
Gene Tools, LLC (Philomath, OR). We injected casper
zebraﬁsh clutches from natural pairwise matings with pro-
gressively increasing doses of each MO into 1- to 4-cell stage
embryos.15 After titration experiments, we used a dose of 12
and 10 ng for the assays for the exon 2 and 4MOs, respectively.
For rescue experiments, wild-type and mutant SQSTM1
constructs were subcloned into the pCS2+ vector, linearized,
and in vitro transcribed with the SP6 mMessage mMachine kit
(Ambion, Austin, TX). Larvae were phenotyped at 3 days
postfertilization. Permeabilized ﬁxed embryos were incubated
with anti–α-acetylated tubulin (1:1000; T7451, Sigma-Aldrich)
overnight at room temperature. Larvae were stained with Alexa
Fluor 488 goat anti-mouse IgG (1:500; A21207, Invitrogen).
Dorsal images of the cerebellum were obtained with the Zeiss
AxioCam microscope and then qualitatively scored for struc-
tural integrity. All experiments were performed with triplicate
batches.
Statistical analysis
For ATP content and complex V activity data comparisons,
statistical analyses were performed with the Student t test. For
the other in vitro and in vivo comparisons, statistical analyses
used a χ2 test. In all comparisons, statistical signiﬁcant dif-
ferences were assumed with p < 0.05.
Data availability
Any data not published within the article will be shared on
request.
Results
Clinical characterization
Family 1
The 2 aﬀected individuals were 41- and 35-year-old male
siblings born to healthy consanguineous parents (third
cousins) who originated from a small village of central Italy
(ﬁgure 1A). They shared the same phenotype and exhibited
a similar clinical history. The disorder manifested at the age of
6 and 12 years, respectively, and consisted of a slowly pro-
gressive syndrome characterized by cerebellar ataxia, severe
hypotonia, bilateral dysmetria, intentional tremor, dysarthria,
nystagmus in all position of gaze, ophthalmoparesis, which
was more pronounced in the vertical gaze, dyskinesia with
bilateral choreoathetotic movements, mild cognitive impair-
ment, and hypergonadotropic hypogonadism. A muscle bi-
opsy performed to explore for a possible mitochondrial
disorder documented the absence of mitochondrial structural
abnormalities in the presence of a mild reduction of mito-
chondrial respiratory chain enzyme activities of complexes
I-II-IV (residual activity 50%–60%). On the basis of the pe-
culiar association of features and progression of disease, the 2
individuals were supposed to have a previously unrecognized
neurodegenerative disorder.
Both siblings have been treated with coenzyme Q10 (150 mg
twice daily) and vitamin E (300 mg/d). Dyskinesia responded
dramatically to therapy with L-DOPA (Sinemet, 50 mg 3 times
daily), 5-hydroxy tryptophan (50 mg 3 times daily), and tri-
hexyphenidyl (2 mg 3 times daily). Since then, the clinical
manifestations have appeared stable for several years. Cur-
rently, they are still able to walk with small aid and to manage
simple occupational and social tasks, although both individuals
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manifest a severe cerebellar syndrome, gaze palsy, and mild
impairment of ≥1 cognitive domains (video). The oldest
brother had a Mini-Mental State Examination score of 20, and
his executive, mnesic, and attentive functions were impaired at
neuropsychological evaluation. The youngest sibling showed
a Mini-Mental State Examination score of 24 with selective
deﬁcit of executive functions. They do not exhibit pyramidal
signs, extrapyramidal symptoms (at the side of involuntary
movements), neurosensory impairment, hearing loss, or any
other ocular abnormality.
Hypergonadotropic hypogonadism with low normal testos-
terone and small testicles was evident since the ﬁrst stage of
the disease in both patients. There was no other endocrino-
logic dysfunction or manifestation of bone abnormalities. CSF
chemical and immunologic analyses and serum coenzyme Q,
lactate, creatine kinase, folate, homocysteine, and vitamins B12
and E were normal, and extensive search for known causes of
ataxia was negative. During the 26 years of follow-up, 24-hour
Holter EEG, polysomnography, EMG, electroneurography,
somatosensory and motor evoked potentials, spine MRI, and
respiratory and cardiac evaluation were repeatedly normal.
Brain imaging was unrevealing (ﬁgure 2, A–F), although it
showed a mild, subtle cerebellar atrophy developing over time
in the ﬁrst brother, evident in a comparison of the ﬁrst (at 12
years old) and last (at 38 years old) MRI examinations, and
an enlarged cisterna magna in the second brother. Proton
magnetic resonance brain spectroscopy demonstrated a lactate
peak in ventricular CSF barely visible in basal ganglia (ﬁgure 2,
G and H), while choline, creatine, and N-acetylaspartate were
normal. Dopamine transporter scan revealed a small bilateral
reduction of dopamine transporters uptake in the basal ganglia.
Consistent with the cognitive proﬁle of both sibs, 99mTc-
HMPAO SPECT showed hypoperfusion of right and left
frontal lobes in both patients and right parietal cortex andmild
right cerebellum hypoperfusion in the older brother (ﬁgure 2, I
and J). SPECT examinations displayed the same imaging
pattern over a 5-year period.
Family history was negative, and there was no record of
individuals with a similar condition originating from this vil-
lage. Neurologic examination and endocrinologic assessment
of both parents were normal. None of them showed PDB
features. Sequencing of the most common ataxia-associated
disease genes and mitochondrial DNA did not provide any
insights.
Figure 1 Pedigrees of the 3 families included in the study and location of the identified homozygous SQSTM1mutations
(A) Family trees. Squares indicatemales; circles indicate females. Solid symbols indicate affected individuals; open symbols represent unaffected relatives. (B)
Sequence chromatograms showing homozygosity for the SQSTM1mutations identified in affected members of the 3 families. (C) Functional and structural
domains of SQSTM1 and localization of the identified mutations. KIR = Keap1-interacting; LIR = LC3-interaction region; PB1 = Phox 1 and Bem1p; TRAF6 =
tumor necrosis factor receptor–associated factor 6; UBA = ubiquitin-associated; ZZ = zinc finger.
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Family 2
This consanguineous Iranian family included 2 aﬀected sibs
and 4 healthy siblings (2 sisters and 2 brothers) (ﬁgure 1A).
Both parents were healthy. The proband is a 33-year-old
woman who was born with low birth weight. Her aﬀected
brother, 29 years old, was born with normal neonatal period
without remarkable complaints. Both aﬀected individuals had
mild global delay (e.g., delayed sitting, walking, and speech)
compared to the healthy siblings. They presented with poor
functional abilities but developed milestone regression be-
tween 10 and 12 years of age. At the onset of regression, the
older sister began to show progressive limb ataxia and cog-
nitive and language impairment. She developed muscle
weakness and atrophy aﬀecting predominantly the upper and
lower limbs distally. At the age of 16 years, she lost the ability
to walk independently, and currently she is disabled and
wheelchair bound. The signs and symptoms, disease course,
and age at onset in younger aﬀected brother were similar to
those of his aﬄicted sister, with the severity of the symptoms
appearing slightly milder. He has clumsy gait and can walk
with help, but he is also wheelchair dependent.
The neurologic assessment also showed that both siblings had
cognitive decline, progressive dementia, and additional signs
of cerebellar dysfunction, including dysdiadochokinesis, dys-
metria, and dysarthria. They both also showed abnormal
movements such as dystonia and chorea-athetosis, amyo-
trophy of the hands, and hyperreﬂexia. Both patients lost their
language ﬂuency and developed similar behavioral and psy-
chiatric manifestations, including mutism, executive dys-
function, and apathy. Additional clinical features in both
patients include vertical gaze palsy, abnormal saccadic and
pursuit eye movements, oculomotor apraxia and orofacial
apraxia, urinary incontinence, and pseudobulbar palsy. EMG
and nerve conduction velocities were normal, excluding both
a neurogenic and a myogenic process as the cause of the
Figure 2 Brain imaging
Brain MRI of the affected siblings of family 1: (A–C) F1:V.5 (age 38 years) and (D–F) F1:V.6 (age 31 years). (A, B, D, E) Axial and (C and F) coronal fast spin echo T2
images document the absence of any gross anomaly (enlarged cisterna magna in patient F1:V.6), cortical/cerebellar atrophy, or iron accumulation in basal
ganglia. Single-voxel proton magnetic resonance brain spectroscopy using intermediate echo time (144 milliseconds) in patient F1:V.5 documenting an
inverted doublet of lactate at 1.33 ppm (G) visible at the level of the ventricular CSF (white arrow) and (H) barely visible in basal ganglia. (I) 99mTc-HMPAO SPECT
transaxial images (from the vertex to the cerebellum) in patient F1:V.5 shows mild to moderate reduction in radiotracer uptake (hypoperfusion) in the right
parietal cortex and in the right and left frontal cortices, aswell as asymmetric radiotracer uptake in the cerebellar hemispheres (right < left). (J) In patient 2,mild
reduction in radiotracer uptake (hypoperfusion) is documented in the right and left frontal cortices, but no perfusion asymmetry is seen in the cerebellar
hemispheres.
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weakness. Brain MRI was not performed, but EEG and
hearing and vision assessments carried out in the aﬀected boy
were normal.
Family 3
The consanguineous extended Iranian family included 12
children from 3 nuclear families, of which 3 girls and 4 boys
between 16 and 39 years of age were aﬀected (ﬁgure 1A). All
aﬀected individuals had a remarkably similar course with
progressive diﬃculty in standing up from ﬂoor, unsteady gait,
coordination and balance problems, ataxia, and cognitive
decline starting at ≈10 to 11 years of age. The disease pro-
gressed until the age of 14 to 15 years, and then the pro-
gression decelerated. The last clinical examination revealed
ataxia, dysarthria, vertical gaze palsy, and hyperreﬂexia in all
individuals. They showed dysarthria and behavioral abnor-
malities, including temper and aggression. Hearing and vision
were normal. None of them is currently wheelchair bound.
Brain imaging, muscle biopsy, and EMG were not available.
Clinical ﬁndings for the aﬀected individuals from the 3 fam-
ilies are summarized in the table.
Molecular analyses
Family 1
WES data annotation predicted 12,420 high-quality non-
synonymous changes and variants aﬀecting splice sites.
Among them, 310 clinically associated, private/rare variants
were retained. Since the documented consanguinity, data
ﬁltering was directed to identify homozygous variants
compatible with a recessive inheritance model. After the
exclusion of genes with variants predicted as benign by
combined annotation-dependent depletion (CADD) and
MetaSVM, prioritization and variant validation and cose-
gregation analysis allowed the identiﬁcation of a previously
unreported homozygous variant aﬀecting the exon 2 splice
donor site c.301+2T>A (NM_003900.4) in SQSTM1 as the
only excellent candidate underlying the disorder (ﬁgure 1B).
Reverse transcriptase PCR analysis documented aberrant
processing of the SQSTM1 transcript in patients, resulting in
skipping of exon 2 (ﬁgure 3A) and predicting a shorter
protein lacking 34 amino acids of the N-terminal Phox and
Bem1p (residues 21–103) domains (ﬁgure 1C), which me-
diate protein self-oligomerization.6
Table Clinical and neuroradiologic features of the 11 affected individuals carrying homozygous inactivatingmutations in
SQSTM1 included in the present study and their frequency in all SQSTM1mutation–positive individuals reported so
far
F1:
V.5
F1:
V.6
F2:
IV.1
F2:
IV.4
F3:
IV.1
F3:
IV.3
F3:
IV.4
F3:
IV.5
F3:
IV.10
F3:
IV.11
F3:
IV.12
Haack
et al.11
All
cases
Sex M M F M F F M M F M M 7 F/2M 11 F/
9 M
Age at onset, y 6 12 10–12 10–12 10 9 10 10 10 11 10 7–15 6–15
Age at last examination,
y
41 35 33 29 30 29 28 16 26 17 39 12–45 12–45
Cerebellar ataxia + + + + + + + + + + + 9/9 20/20
Dysarthria + + + + + + + + + + + 9/9 20/20
Cognitive impairment + + + + + + + + + + + 8/9 19/20
Gaze palsy + + + + + + + + + + + 7/9 18/20
Dystonia − − + + − − − − − − − 7/9 9/20
Dyskinesia + + + + − − − − − − − 4/9 8/20
Motor neuron disorder − − − − − − − − − − − 2/9 2/20
Hypergonadotropic
hypogonadism
+ + ND ND ND ND ND ND ND ND ND ND 2/2
MRI: no cerebellar
atrophy
+ + ND ND ND ND ND ND ND ND ND 4/8 6/10
MRI: mild cerebellar
atrophy
− − ND ND ND ND ND ND ND ND ND 4/8 4/10
MRI: hyperintense basal
ganglia
− − ND ND ND ND ND ND ND ND ND 2/8 2/10
Iron accumulation on
basal ganglia
− − ND ND ND ND ND ND ND ND ND 2/8 2/10
Abbreviations: ND = not determined; + = present; − = absent.
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Family 2
We performed WES on the DNA from the proband (IV.1).
On the assumption of autosomal recessive inheritance and the
presence of consanguinity, we prioritized all the homozygous
private/rare variants with predicted functional eﬀect residing
within blocks of homozygosity. With this ﬁltering approach,
a truncating dinucleotide change, c.934_936delinsTGA in
SQSTM1, predicting premature termination (p.Arg312*) of
the protein emerged as the best disease-causing variant (ﬁgure
1B). The variant was located within an ≈8-Mb region of ho-
mozygosity, had not previously been reported, and was vali-
dated by Sanger sequencing, which also conﬁrmed
cosegregation with the disease in the family.
Family 3
We analyzed the extended family by homozygosity mapping
using high-resolution SNP genotyping on 6 aﬀected individ-
uals. The analysis identiﬁed a single shared region of≈2Mb on
chromosome 5q35.3 delimited by rs340121 and rs2545083.
Copy number variation analysis ruled out the occurrence of
any potentially pathogenic structural change. Filtering by po-
sition the functionally relevant rare/private variants annotated
by WES in an aﬀected member (IV.11) identiﬁed a homozy-
gous frameshift variant in SQSTM1 (c.875_876insT) pre-
dicted to cause premature termination (p.Asp292Aspfs*9).
The variant cosegregated with the phenotype, with all aﬀected
family members being homozygous (ﬁgure 1B), and was ab-
sent from public databases.
Biochemical analyses
While the c.875_876insT and c.934_936delinsTGA changes
predicted to result in a prematurely truncated protein, the
splice site change, c.301+2T>A, could either result in a func-
tionally defective protein or promote accelerated degradation.
To characterize the functional eﬀect of the splice site change,
we analyzed the SQSTM1 levels in primary skin ﬁbroblasts
obtained from the 2 sibs and their parents of family 1, doc-
umenting an almost completely abolished expression of the
mutant protein (ﬁgure 3B). Treatment with MG132, a pro-
teosomal inhibitor, resulted in restored levels of mutant
protein, while baﬁlomycin A1, an inhibitor of autophagy,
was not associated to any signiﬁcant change in expression,
providing evidence of accelerated degradation of the mutant
via proteosome (ﬁgure 3, C and D, data available from
Dryad, ﬁgure 1, doi.org/10.5061/dryad.r1vp879). Besides
the accelerated degradation, we tested possible proper re-
sidual function of the SQSTM1 mutant. Because SQSTM1
is known to play a role in selective autophagy by directing
autophagic uptake of proteins via its interaction with LC3,16
we evaluated whether mutant SQSTM1 could bind to LC3
by confocal microscopy analysis. In contrast to cells
expressing wild-type SQSTM1, we did not appreciate the
colocalization of SQSTM1 bodies and LC3 in patient
ﬁbroblasts treated with MG132 to block the accelerated
degradation of the disease-associated SQSTM1 mutant,
documenting its impaired binding to LC3 (data available
from Dryad, ﬁgure 2, doi.org/10.5061/dryad.r1vp879).
Figure 3 Effect of the c.301+2T>A change on transcript
processing and protein stability
(A) The homozygous c.301+2T>A substitution causes skipping of coding
exon 2. Amplification of the cDNA fragment encompassing coding exons 1 to
4 reveals an aberrant PCR product lacking exon 2 in the 2 affected siblings;
wild-type and aberrant processed transcripts are observed in both parents
(top). Sequencing of the mature SQSTM1 transcript from affected individual
F1:V.5 documents skipping of coding exon 2 and the preservation of the
phase of the reading frame (bottom). (B) Western blot analysis performed
on skin fibroblasts from individual F1:V.5 (right), the unaffected mother
(middle), and an unrelated individual (left), indicating that the mutated
SQSTM1 protein lacking the amino acid portion encoded by exon 2 (arrow)
has a dramatically reduced level compared to the wild-type protein. (C)
Treatment of fibroblasts with MG132 (6 hours), an inhibitor of proteasome
function, results in a marked increased level of the SQSTM1 mutant, in-
dicating that this protein is rapidly degraded via proteasome. (D) Incubation
with bafilomycin A1 (baf) and Earle balanced salt solution (EBSS) (6 hours)
does not result in any significant change in the level of themutated SQSTM1
protein, ruling out a major role of autophagy in the degradation of the
SQSTM1 mutant.
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To explore whether the accelerated degradation and impaired
LC3 binding of the SQSTM1 mutant might aﬀect the auto-
phagic pathway, we ﬁrst analyzed levels and processing of
LC3. Primary control and patient ﬁbroblasts were incubated
in EBSS for 2, 4, and 6 hours, with and without the addition of
the lysosomal inhibitor baﬁlomycin A1. We evaluated LC3I
and LC3II levels byWestern blot analysis and observed LC3II
accumulation in SQSTM1-deﬁcient cells compared with
controls in the absence of the inhibitor but no signiﬁcant
diﬀerences between control and patient cells after treatment
with baﬁlomycin A1 (ﬁgure 4A). These results were con-
ﬁrmed by confocal laser scanner microscopy analysis (ﬁgure
4B) and suggested a delay in or defective activation of the
autophagic process. To further explore the extent of dysre-
gulation of the autophagic ﬂux, we monitored the emission of
ﬂuorescence of a BSA derivative (DQ-BSA) conjugated to
a self-quenched ﬂuorophore in patient ﬁbroblasts and control
cells left in starvation for 5 and 16 hours to induce autophagy.
We did not observe dequenched DQ-BSA in patient cells over
the time period (ﬁgure 5A). Overall, the collected data in-
dicated a slowdown of the autophagic ﬂux in cells expressing
the mutant protein, possibly because of a less eﬃcient priming
of the process promoting autophagosome formation.
Several reports have described SQSTM1 as a component of
protein aggregates containing polyubiquitinated proteins.16,17
To test the eﬀect of loss of SQSTM1 function in the forma-
tion and degradation of inclusion bodies containing poly-
ubiquitinated protein aggregates, control and patient
ﬁbroblasts were stained with an anti-ubiquitin monoclonal
antibody recognizing polyubiquitinated proteins after treat-
ment with puromycin (2 hours) to induce formation of
ubiquitin-containing bodies. As expected, we observed ef-
ﬁcient induction of SQSTM1-positive ubiquitin-containing
bodies in control cells, while a signiﬁcantly reduced num-
ber was detected in patient cells (ﬁgure 5B), indicating
impaired formation of inclusion bodies containing poly-
ubiquitinated proteins in primary ﬁbroblasts lacking
SQSTM1 function.
Because of the important role of SQSTM1 in selective
autophagy of damaged mitochondria,18 we also assessed
the consequences of the impaired SQSTM1 function on
mitochondrial clearance in patient ﬁbroblasts. We evalu-
ated the mitochondrial network by TOMM20 staining. In
regular medium, control and patient cells displayed
a widespread and regular tubular organization of
Figure 4 Investigation of the autophagic flux
(A) Microtubule-associated protein 1A/1B-light chain (3LC3) levels were analyzed in control and patient fibroblasts treated with Earle balanced salt solution
(EBSS) for different times. Western blot analysis shows that LC3II accumulates in patients’ fibroblasts. After incubation of the cells in EBSS and treatment with
200 nmol/L bafilomycin (2 hours), no significant differences were seen between control and patient cells. (B) Confocal laser scanner microscopy analysis was
performed in the same experimental conditions reported in panel A and confirms the same findings. Bars correspond to 40 μm.
e326 Neurology | Volume 91, Number 4 | July 24, 2018 Neurology.org/N
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
mitochondria. However, after CCCP-promoted induction
of mitochondrial depolarization, we observed clustering of
mitochondria around the nuclei in control ﬁbroblasts but
no appreciable modiﬁcations in patient ﬁbroblasts (data
available from Dryad, ﬁgure 3A, doi.org/10.5061/dryad.
r1vp879). We also examined mitochondrial ATP pro-
duction and respiratory chain enzyme activities, observing
signiﬁcantly reduced total cellular ATP content in patient
ﬁbroblasts compared to controls in regular medium
(−28%) and an even more reduced content (−48%) in
galactose medium, reﬂecting a lower eﬃciency of ATP
production by oxidative phosphorylation (OXPHOS) in
stress condition. We conﬁrmed these data by indirect
evaluation of the OXPHOS status in patient ﬁbroblasts by
measuring the ATP synthesis in puriﬁedmitochondria, which
displayed decreased activity (≈40% compared to controls, data
available from Dryad, ﬁgure 3B, doi.org/10.5061/dryad.
r1vp879), conﬁrming the generalized partial reduction of mi-
tochondrial respiratory chain enzyme activities previously
documented by muscle biopsy.
In vivo analysis
Given the evidence that suppression of genes causative for
Gordon-Holmes syndrome can be modeled reliably in the
developing zebraﬁsh embryo, especially with regard to the
core phenotype of cerebellar hypoplasia,19 we used this
model system to examine the consequences of suppression
of SQSTM1 function in vivo. The zebraﬁsh genome con-
tains a single sqstm1 ortholog (NP_001299842; 44%
identity and 58% similarity with the human gene). We
designed a splice-blocking MO targeting the donor splice
site of exon 2 to mimic the eﬀect of the disease-causing
variant aﬀecting transcript processing, driving suppression
of sqstm1 with high eﬃciency due to skipping of exon 2 of
the endogenous mRNA. Then, we evaluated the eﬀect of
the MO-induced sqstm1 knockdown on the structural
integrity of the cerebellum at 3 days postfertilization.
Across duplicate experiments (50–100 embryos per in-
jection), we found structural cerebellar defects in ≈60% of
embryos, ranging from depletion of the axonal con-
nections across the midline of the cerebellum to complete
atrophy (ﬁgure 6). The observed phenotype was speciﬁc:
the larvae displayed no other overt pathology that might
indicate toxicity (body length, timing of swim bladder,
edema, or any other apparent gross morphologic defects).
Furthermore, coinjection of human wild-type SQSTM1
mRNA was able to rescue the phenotype (ﬁgure 6). Dif-
ferent from what was observed for the wild-type allele, coin-
jection of the disease-associated SQSTM1D69–100 cDNA with
sqstm1 MO was unable to rescue the phenotype (ﬁgure 6),
further supporting the loss-of-function eﬀect of the disease-
causing mutation. Testing of a second, nonoverlapping MO
Figure 5 Analysis of autophagic flux and formation of inclusion bodies containing ubiquitinated proteins
(A) Primary fibroblasts were incubated with bovine serum albumin derivative (dye-conjugated [DQ] BSA) conjugated to a self-quenched fluorophore (10 μg/
mL) for 1 hour at 37°C in complete culture medium and then left in a starvation medium for 5 and 16 hours to induce autophagy. Cells were mounted on
coverslips and immediately analyzed by confocal microscopy. Dequenched DQ-BSA was not observed over the time period of 16 hours in patient cells. (B)
Primary fibroblasts obtained from one of the 2 affected sibs (right) and an unaffected individual (left) were treated with puromycin (5 μg/mL) for 2 hours to
induce formation of polyubiquitin-positive bodies. Cells were then fixed and stainedwith SQSTM1 (green) and FK1 (red) antibodies. Images are representative
of 300 analyzed cells. In all panels, bars correspond to 40 μm.
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against the donor site of exon 4 conﬁrmed these ﬁndings (data
not shown).
Discussion
Here, we report the clinical characterization of an early-onset,
variably progressive, neurodegenerative disorder aﬀecting 11
individuals from 3 unrelated families caused by 3 distinct
inactivating homozygous mutations in SQSTM1. We describe
the natural history of this condition for the 2 siblings from
family 1 who have been followed up for >20 years. Functional
studies performed in patient ﬁbroblasts demonstrated that
defective SQSTM1 function is associated with both a slow-
down of the autophagic ﬂux and impaired production of
ubiquitin-positive protein aggregates in response to misfolded
protein stress. Finally, morpholino-induced sqstm1 down-
modulation in zebraﬁsh was shown to cause a reproducible
phenotype characterized by structural anomalies of the
cerebellum.
Continuous turnover of proteins and organelles is crucial for
the maintenance of cellular homeostasis.20 In neurons, which
cannot dilute protein aggregates or dysfunctional organelles
by cell division, eﬃcient degradation pathways are essential
for maintaining cellular health and long-term survival.21–25
Figure 6 In vivo analysis in zebrafish embryos
(A) Representative dorsal images of
anti–α-tubulin (acetylated state)–
stained larvae from 4 experimental
conditions: control, sqstm1 morpho-
lino (MO) injected, sqstm1_MO+
SQSTM1_WT, and sqstm1_MO+
SQSTM1_p.69-100del. Blowups from
the highlighted area in panel A show-
ing in detail the cerebellar structures
in each of the 4 respective conditions
presented. (B) Quantification of the
qualitative scoring assaying the cere-
bellar integrity across 3 biological
replicas.
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SQSTM1 contributes to these clearance systems26 and has
been reported to localize to a variety of ubiquitin-positive
neuropathologic inclusions27–29 and to protect against mis-
folded protein stress by promoting the formation of ubiquitin-
positive inclusions.17 Consistently, the presently collected
data documented defective stress-promoted ubiquitin-
positive protein aggregate formation in SQSTM1-deﬁcient
cells. Accumulated evidence also indicates that SQSTM1 ac-
tively contributes to the autophagic degradation of ubiquiti-
nated proteins.16,17,30 While defective cargo assembly as
a result of impaired SQSTM1 function might not exert a cy-
totoxic eﬀect in dividing cells, it is likely to have adverse
consequences on postmitotic cells.
Besides its function as an autophagy adaptor, SQSTM1 con-
tributes to the assembly of the molecular platforms responsible
for autophagosomes formation via self-oligomerization and
plays a priming role in autophagosome biogenesis.31 The
present data suggest that lack of SQSTM1 may weaken the
phagophore assembly and cause a slowdown of the autopha-
gosome turnover, as shown by the accumulation of LC3 after 2
hours of starvation and reduced responsiveness of cells after
treatment with baﬁlomycin.
Conﬂicting data have been obtained on the consequences of
defective SQSTM1 function on mitochondrial function and
clearance.11,18,32,33 In line with previous ﬁndings,11 we ob-
served an aberrant mitochondria perinuclear clustering after
inducingmitochondrial depolarization and defectiveOXPHOS
function, which was consistent with a mild reduction of com-
plexes I-II-IV activity in muscle biopsy of F1:V.5 and a small
lactate peak in the ventricular CSF in the same patient. These
data suggest that secondary mitochondrial dysfunction might
contribute to pathogenesis, as documented in other neurode-
generative diseases.34
Major features of the neurodegenerative disorder shared by the
11 aﬀected individuals from the 3 families include ataxia, dys-
metria, dysarthria, gaze palsy, cognitive decline, dyskinesia,
dystonia, and, in 2 patients, hypergonadotropic hypogonadism.
These are in line with the recent report by Haack et al.,11 who
described 3 diﬀerent homozygous inactivating mutations in
SQSTM1 in 9 patients from 4 unrelated families. Overall, the
striking homogeneity in the 20 aﬀected patients indicates that
the core features of this newly recognized, recessive neurode-
generative disorder include childhood-onset cerebellar ataxia
(6–15 years), oculomotor involvement, cognitive decline, and
dystonia and/or dyskinetic movements (table). The cerebellar
ataxia occurred invariantly. Ophthalmoparesis characteristi-
cally involves the vertical gaze ﬁrst and all ocular movements
subsequently. Dystonia or dyskinesia has been recorded in 9
and 8 patients, respectively (table), but severe and generalized
dystonia was documented in 1 family only,11 in association
with a pyramidal syndrome and iron accumulation in basal
ganglia. In the 2 siblings of the present family 1, dyskinesia
responded well to low doses of L-DOPA, 5-hydroxy-
tryptophan, and trihexyphenidyl treatment, with no adverse
eﬀects or any requirement of increased dosage during the
follow-up, although any attempt to withdraw was associated
with reappearance of the symptoms. Of note, dopamine
transporter scan revealed a small bilateral reduction of do-
pamine transporter uptake in the basal ganglia in both sib-
lings. Cognitive impairment is another consistent clinical
feature of the disorder; it was recorded in all but 1 individual.
In the 2 aﬀected siblings of family 1, it was documented since
the onset of disease and appeared stable over time. Neuro-
psychological assessment demonstrated impairment of ex-
ecutive functions in both sibs and compromised mnesic and
attentive functions in the oldest. Accordingly, SPECT
showed hypoperfusion of right and left frontal lobes in both
patients, extended to the right parietal cortex in the ﬁrst
brother, in the absence of any evidence of atrophy in the
corresponding areas at the brain MRI.
A major distinctive ﬁnding of the disorder is the relatively mild
pattern of cerebellar atrophy despite the particularly severe
form of cerebellar syndrome that appears to represent an in-
formative feature in diﬀerential diagnosis in the rapidly
growing, heterogeneous group of spinocerebellar ataxias. In
terms of the course of the disease, it was progressive in most
patients, with some losing the ability to walk before the age of
20 years, even though loss of motor or cognitive performances
does not represent an invariant feature. In the absence of any
treatment details, it is diﬃcult to ascertain whether the rela-
tively stable course in the 2 siblings of family 1 is the result of
their early treatment with antioxidants and L-DOPA or simply
due to a particularly slow progression of disease. Hyper-
gonadotropic hypogonadism was documented in both the
aﬀected siblings of family 1 but could not be investigated in
aﬀected members from families 2 and 3 and was not men-
tioned among the previously reported SQSTM1 mutation–
positive patients.11 Hypogonadism has remarkable association
with variable neurologic disorders, including cerebellar
ataxia,35–37 and has been recently reported as an associated
feature of a neurodegenerative syndrome characterized by
ataxia, dementia, and hypogonadotropic hypogonadism
caused bymutations inRNF216 andOTUD4,19 both encoding
proteins implicated in ubiquitin-mediated protein degradation.
A dedicated assessment is required to establish deﬁnitely any
association between hypogonadism and this neurodegenera-
tive disorder.
Heterozygous SQSTM1 mutations have previously been
reported in a subset of patients with amyotrophic lateral scle-
rosis and frontotemporal lobar degeneration, PDB, and distal
myopathy with rimmed vacuoles,5,8,10,38,39 which suggests that
SQSTM1 is critical for several pathophysiologic pathways and
that the individual molecular lesion, environmental factors, and
other modiﬁer loci are important in determining expressivity.
The present ﬁndings provide further data on the relevance
of compromised SQSTM1 function in neurodegeneration,
linking a distinctive early-onset and variably progressive neu-
rodegenerative trait to the defective clearance of poly-
ubiquitinated aggregates.
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